Navigation Links
Axia Group (AGIJ:PK) Reaches Agreement for Development and Marketing of Psoriasis Products

OTTAWA, Ontario, Aug. 11, 2011 /PRNewswire/ -- Axia Group (Pink Sheets: AGIJ, Collagenna Skin Care Products announced that is has reached an agreement with Prime Pharma, a subsidiary of the TSE publicly traded company Allegiance Equity Corporation (TSXV: ANQ.V) for the marketing and development of Mahonia Products which have been clinically proven to help relieve the symptoms related to psoriasis.

Prime Pharma's premier product is the Relieva cream, an over the counter psoriasis cream which has been reformulated into a more effective product. The agreement is based upon a joint venture for worldwide, non-internet marketing sales of the Mahonia extract product line, both present and future products.

Company agreement will allow Collagenna access to worldwide patents as well as new patentable technology. With Mahonia as a proven active ingredient, Prime Pharma possesses a patented extract with which the company plans to find innovative ways to help distinguish the company from the competition.

Collagenna plans to commence clinical trials to validate the preliminary testing, and hopes to publish results in the next 30 days.

The company commenced the necessary regulatory paperwork which will allow Collagenna to market Relieva in both Canada and the US. Company expects this process to take around 60 days. In the meantime we will initiate marketing efforts immediately.

An Independent report (Research and Markets) of 2004 on world-wide psoriasis prescription market concluded this market to grow at compound annual rate of 23.6% to over $3.1B worldwide by 2009. According to Global Industry Analysts Inc., Global psoriasis drugs market will exceed $ 7.3 billion dollars by 2015.

Collagenna Skin Care Products specializes in Anti-aging products with an emphasis on Collagen stimulation both topically and internally. The company sells its products mainly through its specialized skin care clinics through its ever expanding network of distribution partners.

More details and updates will be provided shortly and on a timely basis.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Axia Group Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Axia Group Inc. cautions you that any forward-looking information provided by or on behalf of Axia Group Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Axia Group Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Axia Group Inc.'s control. In addition to those discussed in Axia Group Inc.'s press releases, public filings, and statements by Axia Group Inc.'s management, including, but not limited to, Axia Group Inc.'s estimate of the sufficiency of its existing capital resources, Axia Group Inc.'s ability to raise additional capital to fund future operations, Axia Group Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Axia Group Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Axia Group Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

SOURCE Axia Group Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuse Science Partners With the New England Consulting Group to Advance Technology Licensing Efforts in Pharmaceutical and OTC Categories
2. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2011 Results
3. Systech Selects Vantage Consulting Group as their Sales Agent in Puerto Rico
4. Global Pharm Holdings Group Completes Acquisition of Pacific Asia Pharm Investment Group Co., Ltd.
5. Winner Medical Group Inc. to Host Third Quarter 2011 Earning Conference Call on Wednesday, August 10, 2011 at 8:30 a.m. EDT
6. Foundation Venture Capital Group Investment Shows Promise in Diagnosis of Alzheimers Disease Using a Drop of Blood
7. Hanger Orthopedic Group Announces Five Acquisitions Producing $20.2 million of Annual Net Revenue
8. Vantage Health South African Subsidiary Negotiates Supply Agreement With Major South African Retail Group
9. Groupe Athena, Inc. Profits Soar on Record Revenues
10. Hanger Orthopedic Group Celebrates Its 150th Anniversary: Celebrations to Commence with NYSE Bell Ringing on August 10
11. Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015 Oramed Pharmaceuticals ... focused on the development of oral drug delivery systems, ... agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of Technologies ... oral insulin capsule, ORMD-0801, in China ... Macau . The agreements were signed at ...
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... 30, 2015  Hanger, Inc. (NYSE: HGR ) ... the terms of its previously announced consent solicitation (as ... $200,000,000 aggregate principal amount 7⅛% Senior Notes due 2018 ... consent fees payable pursuant to the Consent Solicitation, (ii) ... (iii) the expiration date of the Consent Solicitation.    ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... Stress, anxiety, illness, infection or even a need for eyeglasses can sometimes ... MD, a new pediatric neurosurgeon at Joe DiMaggio Children’s Hospital in Hollywood, Florida, said ... , “Bad headaches that don’t go away, that don’t have any other reason, ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... the driverless vehicle experience this summer, ushering in a new era of publicly ... driverless and electric shuttle, will continue to offer guests an up-close look at ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals with political issues ... it a national news story when Donald Trump makes disparaging remarks about Hillary Clinton’s ... more than anyone wants to admit when it comes to how people are viewed ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... course in Dallas, TX, on January 29 and 30, 2016. The course welcomes ... functions of their practices, to learn how to better succeed in the modern ...
(Date:11/30/2015)... ... 2015 , ... A novel class of antimicrobials that inhibits ... fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according ... analogs that target the functions of SecA, a central part of the general ...
Breaking Medicine News(10 mins):